|
US5741908A
(en)
|
1996-06-21 |
1998-04-21 |
Minnesota Mining And Manufacturing Company |
Process for reparing imidazoquinolinamines
|
|
JP4391592B2
(ja)
*
|
1996-10-25 |
2009-12-24 |
スリーエム カンパニー |
Th2介在性および関連疾患治療のための免疫応答修飾化合物
|
|
UA67760C2
(uk)
|
1997-12-11 |
2004-07-15 |
Міннесота Майнінг Енд Мануфакчурінг Компані |
Імідазонафтиридин та тетрагідроімідазонафтиридин, фармацевтична композиція, спосіб індукування біосинтезу цитокінів та спосіб лікування вірусної інфекції, проміжні сполуки
|
|
CA2330610A1
(en)
*
|
1998-05-07 |
1999-11-11 |
Corixa Corporation |
Adjuvant composition and methods for its use
|
|
US6518280B2
(en)
|
1998-12-11 |
2003-02-11 |
3M Innovative Properties Company |
Imidazonaphthyridines
|
|
US6558951B1
(en)
*
|
1999-02-11 |
2003-05-06 |
3M Innovative Properties Company |
Maturation of dendritic cells with immune response modifying compounds
|
|
US6756382B2
(en)
*
|
1999-06-10 |
2004-06-29 |
3M Innovative Properties Company |
Amide substituted imidazoquinolines
|
|
US6541485B1
(en)
|
1999-06-10 |
2003-04-01 |
3M Innovative Properties Company |
Urea substituted imidazoquinolines
|
|
US6331539B1
(en)
*
|
1999-06-10 |
2001-12-18 |
3M Innovative Properties Company |
Sulfonamide and sulfamide substituted imidazoquinolines
|
|
US6573273B1
(en)
|
1999-06-10 |
2003-06-03 |
3M Innovative Properties Company |
Urea substituted imidazoquinolines
|
|
GB9924351D0
(en)
|
1999-10-14 |
1999-12-15 |
Brennan Frank |
Immunomodulation methods and compositions
|
|
US6376669B1
(en)
|
1999-11-05 |
2002-04-23 |
3M Innovative Properties Company |
Dye labeled imidazoquinoline compounds
|
|
US6916925B1
(en)
|
1999-11-05 |
2005-07-12 |
3M Innovative Properties Co. |
Dye labeled imidazoquinoline compounds
|
|
JP3436512B2
(ja)
*
|
1999-12-28 |
2003-08-11 |
株式会社デンソー |
アクセル装置
|
|
US6894060B2
(en)
*
|
2000-03-30 |
2005-05-17 |
3M Innovative Properties Company |
Method for the treatment of dermal lesions caused by envenomation
|
|
US20020055517A1
(en)
*
|
2000-09-15 |
2002-05-09 |
3M Innovative Properties Company |
Methods for delaying recurrence of herpes virus symptoms
|
|
GB0023008D0
(en)
*
|
2000-09-20 |
2000-11-01 |
Glaxo Group Ltd |
Improvements in vaccination
|
|
UA74852C2
(en)
*
|
2000-12-08 |
2006-02-15 |
3M Innovative Properties Co |
Urea-substituted imidazoquinoline ethers
|
|
US6677347B2
(en)
*
|
2000-12-08 |
2004-01-13 |
3M Innovative Properties Company |
Sulfonamido ether substituted imidazoquinolines
|
|
US6545017B1
(en)
|
2000-12-08 |
2003-04-08 |
3M Innovative Properties Company |
Urea substituted imidazopyridines
|
|
US6667312B2
(en)
*
|
2000-12-08 |
2003-12-23 |
3M Innovative Properties Company |
Thioether substituted imidazoquinolines
|
|
US6660747B2
(en)
|
2000-12-08 |
2003-12-09 |
3M Innovative Properties Company |
Amido ether substituted imidazoquinolines
|
|
US20060142202A1
(en)
*
|
2000-12-08 |
2006-06-29 |
3M Innovative Properties Company |
Compositions and methods for targeted delivery of immune response modifiers
|
|
CA2430206A1
(en)
*
|
2000-12-08 |
2002-06-13 |
3M Innovative Properties Company |
Screening method for identifying compounds that selectively induce interferon alpha
|
|
US6660735B2
(en)
*
|
2000-12-08 |
2003-12-09 |
3M Innovative Properties Company |
Urea substituted imidazoquinoline ethers
|
|
US6677348B2
(en)
|
2000-12-08 |
2004-01-13 |
3M Innovative Properties Company |
Aryl ether substituted imidazoquinolines
|
|
US6525064B1
(en)
|
2000-12-08 |
2003-02-25 |
3M Innovative Properties Company |
Sulfonamido substituted imidazopyridines
|
|
US6545016B1
(en)
|
2000-12-08 |
2003-04-08 |
3M Innovative Properties Company |
Amide substituted imidazopyridines
|
|
US6664264B2
(en)
*
|
2000-12-08 |
2003-12-16 |
3M Innovative Properties Company |
Thioether substituted imidazoquinolines
|
|
US6664260B2
(en)
|
2000-12-08 |
2003-12-16 |
3M Innovative Properties Company |
Heterocyclic ether substituted imidazoquinolines
|
|
US6664265B2
(en)
*
|
2000-12-08 |
2003-12-16 |
3M Innovative Properties Company |
Amido ether substituted imidazoquinolines
|
|
US7226928B2
(en)
*
|
2001-06-15 |
2007-06-05 |
3M Innovative Properties Company |
Methods for the treatment of periodontal disease
|
|
CA2458876A1
(en)
*
|
2001-08-30 |
2003-03-13 |
3M Innovative Properties Company |
Methods of maturing plasmacytoid dendritic cells using immune response modifier molecules
|
|
AU2002360278A1
(en)
*
|
2001-10-12 |
2003-11-11 |
Coley Pharmaceutical Gmbh |
Methods and products for enhancing immune responses using imidazoquinoline compounds
|
|
DK1719511T3
(da)
*
|
2001-11-16 |
2009-04-14 |
Coley Pharm Group Inc |
N-[4-(4-amino-2-ethyl-1H-imidazo[4,5-c]quinolin-1-yl)butyl]methansulfonamid, en farmaceutisk sammensætning omfattende samme, og anvendelse deraf
|
|
IL161786A0
(en)
*
|
2001-11-29 |
2005-11-20 |
3M Innovative Properties Co |
Pharmaceutical formulations comprising an immune
|
|
CA2365732A1
(en)
*
|
2001-12-20 |
2003-06-20 |
Ibm Canada Limited-Ibm Canada Limitee |
Testing measurements
|
|
US6677349B1
(en)
|
2001-12-21 |
2004-01-13 |
3M Innovative Properties Company |
Sulfonamide and sulfamide substituted imidazoquinolines
|
|
US7030129B2
(en)
*
|
2002-02-22 |
2006-04-18 |
3M Innovative Properties Company |
Method of reducing and treating UVB-induced immunosuppression
|
|
US20030190308A1
(en)
*
|
2002-03-19 |
2003-10-09 |
Braun Ralph P. |
Adjuvant
|
|
US20050266024A1
(en)
*
|
2002-03-19 |
2005-12-01 |
Powdermed Limited |
Adjuvant
|
|
AU2003216851B2
(en)
*
|
2002-03-19 |
2008-04-17 |
Powderject Research Limited |
Imidazoquinoline adjuvants for vaccines
|
|
US20030185835A1
(en)
*
|
2002-03-19 |
2003-10-02 |
Braun Ralph P. |
Adjuvant for vaccines
|
|
GB0206461D0
(en)
*
|
2002-03-19 |
2002-05-01 |
Glaxo Group Ltd |
Improvements in vaccination
|
|
GB0211649D0
(en)
*
|
2002-05-21 |
2002-07-03 |
Novartis Ag |
Organic compounds
|
|
WO2003103584A2
(en)
|
2002-06-07 |
2003-12-18 |
3M Innovative Properties Company |
Ether substituted imidazopyridines
|
|
WO2004032829A2
(en)
|
2002-08-15 |
2004-04-22 |
3M Innovative Properties Company |
Immunostimulatory compositions and methods of stimulating an immune response
|
|
US6818650B2
(en)
*
|
2002-09-26 |
2004-11-16 |
3M Innovative Properties Company |
1H-imidazo dimers
|
|
AU2003287316A1
(en)
*
|
2002-12-11 |
2004-06-30 |
3M Innovative Properties Company |
Assays relating to toll-like receptor activity
|
|
WO2004053057A2
(en)
*
|
2002-12-11 |
2004-06-24 |
3M Innovative Properties Company |
Gene expression systems and recombinant cell lines
|
|
JP2006513212A
(ja)
|
2002-12-20 |
2006-04-20 |
スリーエム イノベイティブ プロパティズ カンパニー |
アリール/ヘタリール置換されたイミダゾキノリン
|
|
US7387271B2
(en)
|
2002-12-30 |
2008-06-17 |
3M Innovative Properties Company |
Immunostimulatory combinations
|
|
JP2006517974A
(ja)
*
|
2003-02-13 |
2006-08-03 |
スリーエム イノベイティブ プロパティズ カンパニー |
Irm化合物およびトル様受容体8に関する方法および組成物
|
|
EP1599726A4
(en)
*
|
2003-02-27 |
2009-07-22 |
3M Innovative Properties Co |
SELECTIVE MODULATION OF TLR-MEDIATED BIOLOGICAL ACTIVITY
|
|
WO2004078138A2
(en)
|
2003-03-04 |
2004-09-16 |
3M Innovative Properties Company |
Prophylactic treatment of uv-induced epidermal neoplasia
|
|
US7163947B2
(en)
*
|
2003-03-07 |
2007-01-16 |
3M Innovative Properties Company |
1-Amino 1H-imidazoquinolines
|
|
WO2004080398A2
(en)
*
|
2003-03-07 |
2004-09-23 |
3M Innovative Properties Company |
1-amino 1h-imidazoquinolines
|
|
KR20050109562A
(ko)
*
|
2003-03-13 |
2005-11-21 |
쓰리엠 이노베이티브 프로퍼티즈 컴파니 |
피부의 질을 개선시키는 방법
|
|
WO2004080293A2
(en)
*
|
2003-03-13 |
2004-09-23 |
3M Innovative Properties Company |
Methods for diagnosing skin lesions
|
|
AU2004220465A1
(en)
|
2003-03-13 |
2004-09-23 |
3M Innovative Properties Company |
Method of tattoo removal
|
|
US20040192585A1
(en)
|
2003-03-25 |
2004-09-30 |
3M Innovative Properties Company |
Treatment for basal cell carcinoma
|
|
AU2004229478B2
(en)
*
|
2003-04-10 |
2009-12-24 |
3M Innovative Properties Company |
Delivery of immune response modifier compounds
|
|
US20040265351A1
(en)
*
|
2003-04-10 |
2004-12-30 |
Miller Richard L. |
Methods and compositions for enhancing immune response
|
|
WO2004110991A2
(en)
*
|
2003-06-06 |
2004-12-23 |
3M Innovative Properties Company |
PROCESS FOR IMIDAZO[4,5-c]PYRIDIN-4-AMINES
|
|
US20050032829A1
(en)
*
|
2003-06-06 |
2005-02-10 |
3M Innovative Properties Company |
Process for imidazo[4,5-c]pyridin-4-amines
|
|
CA2533128A1
(en)
*
|
2003-07-31 |
2005-02-10 |
3M Innovative Properties Company |
Bioactive compositions comprising triazines
|
|
JP2007501252A
(ja)
*
|
2003-08-05 |
2007-01-25 |
スリーエム イノベイティブ プロパティズ カンパニー |
免疫応答調整剤を含有する製剤
|
|
WO2005018556A2
(en)
|
2003-08-12 |
2005-03-03 |
3M Innovative Properties Company |
Hydroxylamine substituted imidazo-containing compounds
|
|
CA2535338C
(en)
*
|
2003-08-14 |
2013-05-28 |
3M Innovative Properties Company |
Substituted 1h-imidazo[4,5-c]pyridin-4-amines,1h-imidazo[4,5-c]quinolin -4-amines and 1h-imidazo[4,5-c]naphthyridin-4-amines as immune response modifiers
|
|
US20050048072A1
(en)
*
|
2003-08-25 |
2005-03-03 |
3M Innovative Properties Company |
Immunostimulatory combinations and treatments
|
|
CA2536249A1
(en)
*
|
2003-08-25 |
2005-03-10 |
3M Innovative Properties Company |
Delivery of immune response modifier compounds
|
|
RU2006105101A
(ru)
|
2003-08-27 |
2007-10-10 |
3М Инновейтив Пропертиз Компани (US) |
Арилокси и арилалкиленокси замещенные имидазохинолины
|
|
AU2004268665A1
(en)
*
|
2003-09-02 |
2005-03-10 |
3M Innovative Properties Company |
Methods related to the treatment of mucosal associated conditions
|
|
WO2005023190A2
(en)
*
|
2003-09-05 |
2005-03-17 |
3M Innovative Properties Company |
Treatment for cd5+ b cell lymphoma
|
|
EP1664342A4
(en)
*
|
2003-09-17 |
2007-12-26 |
3M Innovative Properties Co |
SELECTIVE MODULATION OF TLR GENE EXPRESSION
|
|
US8871782B2
(en)
|
2003-10-03 |
2014-10-28 |
3M Innovative Properties Company |
Alkoxy substituted imidazoquinolines
|
|
US7544697B2
(en)
*
|
2003-10-03 |
2009-06-09 |
Coley Pharmaceutical Group, Inc. |
Pyrazolopyridines and analogs thereof
|
|
AR046172A1
(es)
|
2003-10-03 |
2005-11-30 |
3M Innovative Properties Co |
Pirazolopiridinas y sus analogos; composiciones farmaceuticas que los contienen y su uso en la inhibicion de la biosintesis de citocinas
|
|
AU2004285575A1
(en)
*
|
2003-10-31 |
2005-05-12 |
3M Innovative Properties Company |
Neutrophil activation by immune response modifier compounds
|
|
US8598192B2
(en)
|
2003-11-14 |
2013-12-03 |
3M Innovative Properties Company |
Hydroxylamine substituted imidazoquinolines
|
|
CA2545774A1
(en)
*
|
2003-11-14 |
2005-06-02 |
3M Innovative Properties Company |
Oxime substituted imidazo ring compounds
|
|
CA2547085A1
(en)
*
|
2003-11-25 |
2005-06-09 |
3M Innovative Properties Company |
Hydroxylamine and oxime substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines
|
|
AR046781A1
(es)
|
2003-11-25 |
2005-12-21 |
3M Innovative Properties Co |
Derivados de imidazoquinolinas. composiciones farmaceuticas.
|
|
US20050226878A1
(en)
*
|
2003-12-02 |
2005-10-13 |
3M Innovative Properties Company |
Therapeutic combinations and methods including IRM compounds
|
|
JP2007513165A
(ja)
*
|
2003-12-02 |
2007-05-24 |
スリーエム イノベイティブ プロパティズ カンパニー |
Irm化合物を含む併用薬および治療方法
|
|
EP1694674A4
(en)
*
|
2003-12-04 |
2010-07-07 |
3M Innovative Properties Co |
IMIDAZO CYCLIC ETHERS SUBSTITUTED WITH SULFONE
|
|
EP1699792A1
(en)
*
|
2003-12-29 |
2006-09-13 |
3M Innovative Properties Company |
Piperazine, 1,4¨diazepane, 1,4¨diazocane, and 1,5¨diazocane fused imidazo ring compounds
|
|
WO2005066170A1
(en)
|
2003-12-29 |
2005-07-21 |
3M Innovative Properties Company |
Arylalkenyl and arylalkynyl substituted imidazoquinolines
|
|
WO2005067500A2
(en)
*
|
2003-12-30 |
2005-07-28 |
3M Innovative Properties Company |
Enhancement of immune responses
|
|
CA2551399A1
(en)
|
2003-12-30 |
2005-07-21 |
3M Innovative Properties Company |
Imidazoquinolinyl, imidazopyridinyl, and imidazonaphthyridinyl sulfonamides
|
|
WO2005089317A2
(en)
|
2004-03-15 |
2005-09-29 |
3M Innovative Properties Company |
Immune response modifier formulations and methods
|
|
AU2005228150A1
(en)
|
2004-03-24 |
2005-10-13 |
3M Innovative Properties Company |
Amide substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines
|
|
CA2562283A1
(en)
*
|
2004-04-09 |
2005-11-24 |
3M Innovative Properties Company |
Methods, compositions, and preparations for delivery of immune response modifiers
|
|
CA2564855A1
(en)
*
|
2004-04-28 |
2005-10-28 |
3M Innovative Properties Company |
Compositions and methods for mucosal vaccination
|
|
US20050267145A1
(en)
*
|
2004-05-28 |
2005-12-01 |
Merrill Bryon A |
Treatment for lung cancer
|
|
US20080015184A1
(en)
*
|
2004-06-14 |
2008-01-17 |
3M Innovative Properties Company |
Urea Substituted Imidazopyridines, Imidazoquinolines, and Imidazonaphthyridines
|
|
WO2005123080A2
(en)
|
2004-06-15 |
2005-12-29 |
3M Innovative Properties Company |
Nitrogen-containing heterocyclyl substituted imidazoquinolines and imidazonaphthyridines
|
|
US8026366B2
(en)
|
2004-06-18 |
2011-09-27 |
3M Innovative Properties Company |
Aryloxy and arylalkyleneoxy substituted thiazoloquinolines and thiazolonaphthyridines
|
|
WO2006065280A2
(en)
|
2004-06-18 |
2006-06-22 |
3M Innovative Properties Company |
Isoxazole, dihydroisoxazole, and oxadiazole substituted imidazo ring compounds and methods
|
|
EP1765348B1
(en)
*
|
2004-06-18 |
2016-08-03 |
3M Innovative Properties Company |
Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines
|
|
WO2006038923A2
(en)
|
2004-06-18 |
2006-04-13 |
3M Innovative Properties Company |
Aryl substituted imidazonaphthyridines
|
|
US8541438B2
(en)
|
2004-06-18 |
2013-09-24 |
3M Innovative Properties Company |
Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines
|
|
WO2006026470A2
(en)
*
|
2004-08-27 |
2006-03-09 |
3M Innovative Properties Company |
Hiv immunostimulatory compositions
|
|
CA2578975A1
(en)
|
2004-09-02 |
2006-03-16 |
3M Innovative Properties Company |
2-amino 1h imidazo ring systems and methods
|
|
WO2006028962A2
(en)
*
|
2004-09-02 |
2006-03-16 |
3M Innovative Properties Company |
1-alkoxy 1h-imidazo ring systems and methods
|
|
US20080193468A1
(en)
*
|
2004-09-08 |
2008-08-14 |
Children's Medical Center Corporation |
Method for Stimulating the Immune Response of Newborns
|
|
JP2008515928A
(ja)
*
|
2004-10-08 |
2008-05-15 |
スリーエム イノベイティブ プロパティズ カンパニー |
Dnaワクチンのためのアジュバント
|
|
WO2007001448A2
(en)
|
2004-11-04 |
2007-01-04 |
Massachusetts Institute Of Technology |
Coated controlled release polymer particles as efficient oral delivery vehicles for biopharmaceuticals
|
|
AU2005326708C1
(en)
|
2004-12-30 |
2012-08-30 |
3M Innovative Properties Company |
Substituted chiral fused [1,2]imidazo[4,5-c] ring compounds
|
|
KR20070107685A
(ko)
*
|
2004-12-30 |
2007-11-07 |
다케다 야쿠힌 고교 가부시키가이샤 |
1-(2-메틸프로필)-1H-이미다조[4,5-c][1,5]나프티리딘-4-아민 에탄술포네이트 및1-(2-메틸프로필)-1H-이미다조[4,5-c][1,5]나프티리딘-4-아민 메탄술포네이트
|
|
US20080119508A1
(en)
*
|
2004-12-30 |
2008-05-22 |
3M Innovative Properties Company |
Multi-Route Administration Of Immune Response Modifier Compounds
|
|
US8436176B2
(en)
*
|
2004-12-30 |
2013-05-07 |
Medicis Pharmaceutical Corporation |
Process for preparing 2-methyl-1-(2-methylpropyl)-1H-imidazo[4,5-c][1,5]naphthyridin-4-amine
|
|
EP1831226B1
(en)
|
2004-12-30 |
2012-08-08 |
3M Innovative Properties Company |
Chiral tetracyclic compounds inducing interferon biosynthesis
|
|
JP2008526765A
(ja)
*
|
2004-12-30 |
2008-07-24 |
スリーエム イノベイティブ プロパティズ カンパニー |
皮膚転移の処置
|
|
AU2006210392A1
(en)
|
2005-02-04 |
2006-08-10 |
Coley Pharmaceutical Group, Inc. |
Aqueous gel formulations containing immune response modifiers
|
|
JP2008530252A
(ja)
|
2005-02-09 |
2008-08-07 |
コーリー ファーマシューティカル グループ,インコーポレイテッド |
オキシムおよびヒドロキシルアミンで置換されたチアゾロ[4,5−c]環化合物ならびに方法
|
|
AU2006212765B2
(en)
|
2005-02-09 |
2012-02-02 |
3M Innovative Properties Company |
Alkyloxy substituted thiazoloquinolines and thiazolonaphthyridines
|
|
JP2008532933A
(ja)
|
2005-02-11 |
2008-08-21 |
コーリー ファーマシューティカル グループ,インコーポレイテッド |
置換イミダゾキノリン類および置換イミダゾナフチリジン類
|
|
CA2597587A1
(en)
|
2005-02-11 |
2006-08-17 |
Coley Pharmaceutical Group, Inc. |
Oxime and hydroxylamine substituted imidazo[4,5-c] ring compounds and methods
|
|
JP2008530245A
(ja)
|
2005-02-18 |
2008-08-07 |
ノバルティス ヴァクシンズ アンド ダイアグノスティクス, インコーポレイテッド |
尿路病原性菌株由来の抗原
|
|
AU2006214064B2
(en)
|
2005-02-18 |
2012-04-26 |
J. Craig Venter Institute, Inc. |
Proteins and nucleic acids from meningitis/sepsis-associated escherichia coli
|
|
EP1851224A2
(en)
|
2005-02-23 |
2007-11-07 |
3M Innovative Properties Company |
Hydroxyalkyl substituted imidazoquinolines
|
|
US8158794B2
(en)
|
2005-02-23 |
2012-04-17 |
3M Innovative Properties Company |
Hydroxyalkyl substituted imidazoquinoline compounds and methods
|
|
CA2598639A1
(en)
|
2005-02-23 |
2006-08-31 |
Coley Pharmaceutical Group, Inc. |
Hydroxyalkyl substituted imidazonaphthyridines
|
|
EP1850849A2
(en)
|
2005-02-23 |
2007-11-07 |
Coley Pharmaceutical Group, Inc. |
Method of preferentially inducing the biosynthesis of interferon
|
|
JP2008533148A
(ja)
|
2005-03-14 |
2008-08-21 |
スリーエム イノベイティブ プロパティズ カンパニー |
光線性角化症の治療方法
|
|
WO2006107853A2
(en)
|
2005-04-01 |
2006-10-12 |
Coley Pharmaceutical Group, Inc. |
Pyrazolopyridine-1,4-diamines and analogs thereof
|
|
US7943636B2
(en)
|
2005-04-01 |
2011-05-17 |
3M Innovative Properties Company |
1-substituted pyrazolo (3,4-C) ring compounds as modulators of cytokine biosynthesis for the treatment of viral infections and neoplastic diseases
|
|
CA2605808A1
(en)
*
|
2005-04-25 |
2006-11-02 |
3M Innovative Properties Company |
Immunostimulatory compositions
|
|
EP2614709A1
(en)
|
2005-07-18 |
2013-07-17 |
Novartis AG |
Small animal model for HCV replication
|
|
CA2620182A1
(en)
*
|
2005-08-22 |
2007-03-01 |
Dennis A. Carson |
Tlr agonists
|
|
AU2006287270A1
(en)
|
2005-09-09 |
2007-03-15 |
Coley Pharmaceutical Group, Inc. |
Amide and carbamate derivatives of N-{2-[4-amino-2- (ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]-1,1-dimethylethyl}methanesulfonamide and methods
|
|
ZA200803029B
(en)
*
|
2005-09-09 |
2009-02-25 |
Coley Pharm Group Inc |
Amide and carbamate derivatives of alkyl substituted /V-[4-(4-amino-1H-imidazo[4,5-c] quinolin-1-yl)butyl] methane-sulfonamides and methods
|
|
WO2007052055A1
(en)
|
2005-11-04 |
2007-05-10 |
Novartis Vaccines And Diagnostics Srl |
Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
|
|
ES2429170T3
(es)
|
2005-11-04 |
2013-11-13 |
3M Innovative Properties Company |
1H-Imidazoquinolinas sustituidas con hidroxilo y alcoxilo y métodos
|
|
CA2628424A1
(en)
*
|
2005-11-04 |
2007-05-10 |
Novartis Vaccines And Diagnostics S.R.L. |
Adjuvanted influenza vaccines including cytokine-inducing agents
|
|
ES2377884T3
(es)
|
2005-11-04 |
2012-04-02 |
Novartis Vaccines And Diagnostics S.R.L. |
Vacunas contra la gripe que incluyen combinaciones de adyuvantes particulados e inmunopotenciadores
|
|
NZ594482A
(en)
|
2005-11-04 |
2012-11-30 |
Novartis Vaccines & Diagnostic |
Influenza vaccines with reduced amount of oil-in-water emulsion as adjuvant
|
|
US9267937B2
(en)
|
2005-12-15 |
2016-02-23 |
Massachusetts Institute Of Technology |
System for screening particles
|
|
PL2478916T3
(pl)
|
2006-01-27 |
2020-11-16 |
Seqirus UK Limited |
Szczepionki przeciw grypie zawierające hemaglutyninę i białka macierzy
|
|
EP1988896A4
(en)
|
2006-02-22 |
2011-07-27 |
3M Innovative Properties Co |
CONJUGATES TO MODIFY IMMUNE REACTIONS
|
|
US8329721B2
(en)
|
2006-03-15 |
2012-12-11 |
3M Innovative Properties Company |
Hydroxy and alkoxy substituted 1H-imidazonaphthyridines and methods
|
|
CA2646891A1
(en)
*
|
2006-03-23 |
2007-09-27 |
Novartis Ag |
Immunopotentiating compounds
|
|
EP2010530A2
(en)
*
|
2006-03-23 |
2009-01-07 |
Novartis AG |
Methods for the preparation of imidazole-containing compounds
|
|
ATE539079T1
(de)
|
2006-03-23 |
2012-01-15 |
Novartis Ag |
Imidazochinoxalinverbindungen als immunmodulatoren
|
|
WO2007110776A1
(en)
|
2006-03-24 |
2007-10-04 |
Novartis Vaccines And Diagnostics Gmbh & Co Kg |
Storage of influenza vaccines without refrigeration
|
|
WO2008105773A2
(en)
|
2006-03-31 |
2008-09-04 |
Massachusetts Institute Of Technology |
System for targeted delivery of therapeutic agents
|
|
EP2019686B1
(en)
|
2006-03-31 |
2012-07-11 |
Novartis AG |
Combined mucosal and parenteral immunization against hiv
|
|
TW200808739A
(en)
*
|
2006-04-06 |
2008-02-16 |
Novartis Vaccines & Diagnostic |
Quinazolines for PDK1 inhibition
|
|
CA2645832A1
(en)
*
|
2006-04-25 |
2007-11-01 |
Intercell Ag |
Hcv vaccinations
|
|
US8367113B2
(en)
|
2006-05-15 |
2013-02-05 |
Massachusetts Institute Of Technology |
Polymers for functional particles
|
|
US8846697B2
(en)
|
2006-05-31 |
2014-09-30 |
The Regents Of The University Of California |
Purine analogs
|
|
DK2054431T3
(da)
|
2006-06-09 |
2012-01-02 |
Novartis Ag |
Konformere af bakterielle adhæsiner
|
|
CA2655933C
(en)
|
2006-06-23 |
2014-09-09 |
Alethia Biotherapeutics Inc. |
Polynucleotides and polypeptide sequences involved in cancer
|
|
WO2007150030A2
(en)
*
|
2006-06-23 |
2007-12-27 |
Massachusetts Institute Of Technology |
Microfluidic synthesis of organic nanoparticles
|
|
US7906506B2
(en)
|
2006-07-12 |
2011-03-15 |
3M Innovative Properties Company |
Substituted chiral fused [1,2] imidazo [4,5-c] ring compounds and methods
|
|
GB0614460D0
(en)
|
2006-07-20 |
2006-08-30 |
Novartis Ag |
Vaccines
|
|
US20100144845A1
(en)
*
|
2006-08-04 |
2010-06-10 |
Massachusetts Institute Of Technology |
Oligonucleotide systems for targeted intracellular delivery
|
|
EP2586790A3
(en)
|
2006-08-16 |
2013-08-14 |
Novartis AG |
Immunogens from uropathogenic Escherichia coli
|
|
US8178539B2
(en)
|
2006-09-06 |
2012-05-15 |
3M Innovative Properties Company |
Substituted 3,4,6,7-tetrahydro-5H-1,2a,4a,8-tetraazacyclopenta[cd]phenalenes and methods
|
|
NZ575271A
(en)
|
2006-09-11 |
2011-09-30 |
Novartis Ag |
Making influenza virus vaccines without using eggs
|
|
JP2011506264A
(ja)
|
2006-12-06 |
2011-03-03 |
ノバルティス アーゲー |
インフルエンザウイルスの4つの株に由来する抗原を含むワクチン
|
|
US20080149123A1
(en)
|
2006-12-22 |
2008-06-26 |
Mckay William D |
Particulate material dispensing hairbrush with combination bristles
|
|
GB0700562D0
(en)
|
2007-01-11 |
2007-02-21 |
Novartis Vaccines & Diagnostic |
Modified Saccharides
|
|
EP2510946B1
(en)
|
2007-02-07 |
2015-08-05 |
The Regents of The University of California |
Conjugates of synthetic tlr agonists and uses therefor
|
|
US9217129B2
(en)
|
2007-02-09 |
2015-12-22 |
Massachusetts Institute Of Technology |
Oscillating cell culture bioreactor
|
|
US20090074828A1
(en)
*
|
2007-04-04 |
2009-03-19 |
Massachusetts Institute Of Technology |
Poly(amino acid) targeting moieties
|
|
AU2008279584A1
(en)
*
|
2007-04-27 |
2009-01-29 |
Dow Global Technologies Inc. |
Improved production and in vivo assembly of soluble recombinant icosahedral virus-like particles
|
|
PT2185191E
(pt)
|
2007-06-27 |
2012-11-27 |
Novartis Ag |
Vacinas contra a gripe com baixo teor de aditivos
|
|
GB0714963D0
(en)
|
2007-08-01 |
2007-09-12 |
Novartis Ag |
Compositions comprising antigens
|
|
MX2010003642A
(es)
|
2007-10-12 |
2010-08-09 |
Massachusetts Inst Technology |
Nanotecnologia de vacuna.
|
|
GB0810305D0
(en)
|
2008-06-05 |
2008-07-09 |
Novartis Ag |
Influenza vaccination
|
|
GB0818453D0
(en)
|
2008-10-08 |
2008-11-12 |
Novartis Ag |
Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
|
|
WO2009099650A2
(en)
*
|
2008-02-07 |
2009-08-13 |
Carson Dennis A |
Treatment of bladder diseases with a tlr7 activator
|
|
JP5518041B2
(ja)
|
2008-03-18 |
2014-06-11 |
ノバルティス アーゲー |
インフルエンザウイルスワクチン抗原の調製における改良
|
|
US8277812B2
(en)
|
2008-10-12 |
2012-10-02 |
Massachusetts Institute Of Technology |
Immunonanotherapeutics that provide IgG humoral response without T-cell antigen
|
|
US8343497B2
(en)
|
2008-10-12 |
2013-01-01 |
The Brigham And Women's Hospital, Inc. |
Targeting of antigen presenting cells with immunonanotherapeutics
|
|
US8591905B2
(en)
|
2008-10-12 |
2013-11-26 |
The Brigham And Women's Hospital, Inc. |
Nicotine immunonanotherapeutics
|
|
US8343498B2
(en)
|
2008-10-12 |
2013-01-01 |
Massachusetts Institute Of Technology |
Adjuvant incorporation in immunonanotherapeutics
|
|
CN104829714A
(zh)
|
2008-11-03 |
2015-08-12 |
阿莱斯亚生物疗法股份有限公司 |
特异性地阻滞肿瘤抗原的生物活性的抗体
|
|
WO2010088924A1
(en)
|
2009-02-06 |
2010-08-12 |
Telormedix Sa |
Pharmaceutical compositions comprising imidazoquinolin(amines) and derivatives thereof suitable for local administration
|
|
KR20110117705A
(ko)
|
2009-02-11 |
2011-10-27 |
더 리전트 오브 더 유니버시티 오브 캘리포니아 |
톨-유사 수용체 조정제 및 질병의 치료
|
|
WO2010100632A2
(en)
|
2009-03-06 |
2010-09-10 |
Novartis Ag |
Chlamydia antigens
|
|
EP2419129A2
(en)
|
2009-04-14 |
2012-02-22 |
Novartis AG |
Compositions for immunising against staphylococcus aerus
|
|
DE102010018462A1
(de)
|
2009-04-27 |
2011-04-07 |
Novartis Ag |
Impfstoffe zum Schutz gegen Influenza
|
|
EP4183412B1
(en)
|
2009-07-15 |
2024-08-14 |
GlaxoSmithKline Biologicals SA |
Rsv f protein compositions and methods for making same
|
|
CA2768343A1
(en)
|
2009-07-16 |
2011-01-20 |
Novartis Ag |
Detoxified escherichia coli immunogens
|
|
US20110033515A1
(en)
*
|
2009-08-04 |
2011-02-10 |
Rst Implanted Cell Technology |
Tissue contacting material
|
|
GB0918392D0
(en)
|
2009-10-20 |
2009-12-02 |
Novartis Ag |
Diagnostic and therapeutic methods
|
|
GB0919690D0
(en)
|
2009-11-10 |
2009-12-23 |
Guy S And St Thomas S Nhs Foun |
compositions for immunising against staphylococcus aureus
|
|
CN107029223A
(zh)
|
2010-05-26 |
2017-08-11 |
西莱克塔生物科技公司 |
合成纳米载体联合疫苗
|
|
GB201009861D0
(en)
|
2010-06-11 |
2010-07-21 |
Novartis Ag |
OMV vaccines
|
|
DK2606047T3
(en)
|
2010-08-17 |
2017-03-27 |
3M Innovative Properties Co |
COMPOSITIONS AND FORMULATIONS WITH LIPIDIZED IMMUNE RESPONSE-MODIFIING COMPOUND AND PROCEDURES THEREOF
|
|
EP2640190A4
(en)
|
2010-11-05 |
2016-05-11 |
Selecta Biosciences Inc |
MODIFIED NICOTINIC COMPOUNDS AND ASSOCIATED METHODS
|
|
ES3018416T3
(es)
|
2011-01-26 |
2025-05-16 |
Glaxosmithkline Biologicals Sa |
Régimen de inmunización del VRS
|
|
CA2893376A1
(en)
|
2011-03-31 |
2012-10-04 |
Alethia Biotherapeutics Inc. |
Antibodies against kidney associated antigen 1 and antigen binding fragemnts thereof
|
|
RS56748B1
(sr)
|
2011-05-13 |
2018-03-30 |
Glaxosmithkline Biologicals Sa |
Pre-fuzioni rsv f antigeni
|
|
EP3153180A1
(en)
|
2011-06-03 |
2017-04-12 |
3M Innovative Properties Company |
Heterobifunctional linkers with polyethylene glycol segments and immune response modifier conjugates made therefrom
|
|
BR112013031028A2
(pt)
|
2011-06-03 |
2016-11-29 |
3M Innovative Properties Co |
conectores heterobifuncionais com segmentos de polietileno glicol e conjugados de modificadores de resposta imunológica feitos a partir deles
|
|
US20130023736A1
(en)
|
2011-07-21 |
2013-01-24 |
Stanley Dale Harpstead |
Systems for drug delivery and monitoring
|
|
JP2014521687A
(ja)
|
2011-07-29 |
2014-08-28 |
セレクタ バイオサイエンシーズ インコーポレーテッド |
体液性および細胞傷害性tリンパ球(ctl)免疫応答を生成する合成ナノキャリア
|
|
RU2636350C2
(ru)
|
2011-11-07 |
2017-11-22 |
Новартис Аг |
МОЛЕКУЛА, СОДЕРЖАЩАЯ SPR0096 и SPR2021
|
|
KR102072041B1
(ko)
|
2011-12-22 |
2020-01-31 |
앨리오스 바이오파마 인크. |
치환된 뉴클레오사이드, 뉴클레오타이드 및 그의 유사체
|
|
AU2013209234B2
(en)
|
2012-01-09 |
2017-11-09 |
Adc Therapeutics Sa |
Method for treating breast cancer
|
|
WO2013108272A2
(en)
|
2012-01-20 |
2013-07-25 |
International Centre For Genetic Engineering And Biotechnology |
Blood stage malaria vaccine
|
|
US9441007B2
(en)
|
2012-03-21 |
2016-09-13 |
Alios Biopharma, Inc. |
Substituted nucleosides, nucleotides and analogs thereof
|
|
USRE48171E1
(en)
|
2012-03-21 |
2020-08-25 |
Janssen Biopharma, Inc. |
Substituted nucleosides, nucleotides and analogs thereof
|
|
PL2844282T3
(pl)
|
2012-05-04 |
2019-11-29 |
Pfizer |
Antygeny związane z gruczołem krokowym i schematy immunoterapii oparte na szczepionce
|
|
CN103961697A
(zh)
|
2013-02-05 |
2014-08-06 |
日东电工株式会社 |
粘膜给予用疫苗组合物
|
|
CA2840954A1
(en)
|
2013-02-05 |
2014-08-05 |
Nitto Denko Corporation |
Vaccine composition for transdermal or mucosal administration
|
|
CA2840997A1
(en)
|
2013-02-05 |
2014-08-05 |
Nitto Denko Corporation |
Vaccine composition for transdermal administration
|
|
CN103961700A
(zh)
|
2013-02-05 |
2014-08-06 |
日东电工株式会社 |
粘膜给予用疫苗组合物
|
|
CN103961307B
(zh)
|
2013-02-05 |
2019-11-29 |
日东电工株式会社 |
经皮给予用wt1肽癌症疫苗组合物
|
|
CA2840937A1
(en)
|
2013-02-05 |
2014-08-05 |
Nitto Denko Corporation |
Vaccine composition for transdermal administration
|
|
CN103961702B
(zh)
|
2013-02-05 |
2019-04-09 |
日东电工株式会社 |
粘膜给予用wt1肽癌症疫苗组合物
|
|
CN103961701B
(zh)
|
2013-02-05 |
2018-09-14 |
日东电工株式会社 |
疫苗组合物
|
|
CA2841014A1
(en)
*
|
2013-02-05 |
2014-08-05 |
Nitto Denko Corporation |
Tape preparation of wt1 peptide cancer vaccine for transdermal administration
|
|
CA2840941A1
(en)
|
2013-02-05 |
2014-08-05 |
Nitto Denko Corporation |
Wt1 peptide cancer vaccine composition for transdermal administration
|
|
EP2870974A1
(en)
|
2013-11-08 |
2015-05-13 |
Novartis AG |
Salmonella conjugate vaccines
|
|
EP3083618B1
(en)
|
2013-12-17 |
2018-02-21 |
Pfizer Inc |
Novel 3,4-disubstituted-1h-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7h-pyrrolo[2,3-c]pyridazines as lrrk2 inhibitors
|
|
MX377794B
(es)
|
2014-03-26 |
2025-03-10 |
Glaxosmithkline Biologicals Sa |
Antigenos estafilococicos mutantes.
|
|
RU2722149C1
(ru)
|
2015-09-14 |
2020-05-27 |
Пфайзер Инк. |
Новые производные имидазо[4,5-c] хинолинов и имидазо[4,5-c][1,5] нафтиридинов в качестве ингибиторов LRRK2
|
|
US11697851B2
(en)
|
2016-05-24 |
2023-07-11 |
The Regents Of The University Of California |
Early ovarian cancer detection diagnostic test based on mRNA isoforms
|
|
CA3086439A1
(en)
|
2017-12-20 |
2019-06-27 |
3M Innovative Properties Company |
Amide substitued imidazo[4,5-c]quinoline compounds with a branched chain linking group for use as an immune response modifier
|
|
EP4146204A4
(en)
*
|
2020-05-05 |
2024-07-03 |
Virovax LLC |
Vaccine adjuvants
|